These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

208 related items for PubMed ID: 23578274

  • 21. Diane-35 (cyproterone acetate): safety concerns.
    Wooltorton E.
    CMAJ; 2003 Feb 18; 168(4):455-6. PubMed ID: 12591790
    [No Abstract] [Full Text] [Related]

  • 22. [Which contraception for women with increased risk of venous thromboembolism?].
    Julen O, Dubuisson JB, Lourenço AG.
    Rev Med Suisse; 2011 Feb 09; 7(281):351-4, 356. PubMed ID: 21416714
    [Abstract] [Full Text] [Related]

  • 23. Venous and pulmonary thromboembolism and combined hormonal contraceptives. Systematic review and meta-analysis.
    Martínez F, Ramírez I, Pérez-Campos E, Latorre K, Lete I.
    Eur J Contracept Reprod Health Care; 2012 Feb 09; 17(1):7-29. PubMed ID: 22239262
    [Abstract] [Full Text] [Related]

  • 24. Combined hormonal contraception and venous thromboembolism.
    Martínez F, Avecilla A.
    Eur J Contracept Reprod Health Care; 2007 Jun 09; 12(2):97-106. PubMed ID: 17559006
    [Abstract] [Full Text] [Related]

  • 25. What is the risk of venous thromboembolism (VTE) among women taking third-generation oral contraceptives (OCs) in comparison with those taking contraceptives containing levonorgestrel?
    Meurer LN, Slawson JG.
    J Fam Pract; 2001 Feb 09; 50(2):108. PubMed ID: 11219554
    [No Abstract] [Full Text] [Related]

  • 26. Progestin-only contraception and venous thromboembolism.
    Blanco-Molina MA, Lozano M, Cano A, Cristobal I, Pallardo LP, Lete I.
    Thromb Res; 2012 May 09; 129(5):e257-62. PubMed ID: 22425318
    [Abstract] [Full Text] [Related]

  • 27. Combined hormonal contraception and the risk of venous thromboembolism: a guideline.
    Practice Committee of the American Society for Reproductive Medicine. Electronic address: ASRM@asrm.orgAmerican Society for Reproductive Medicine, Birmingham, Alabama., Practice Committee of the American Society for Reproductive Medicine.
    Fertil Steril; 2017 Jan 09; 107(1):43-51. PubMed ID: 27793376
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Risk of recurrent venous thromboembolism on progestin-only contraception: a cohort study.
    Le Moigne E, Tromeur C, Delluc A, Gouillou M, Alavi Z, Lacut K, Mottier D, Le Gal G.
    Haematologica; 2016 Jan 09; 101(1):e12-4. PubMed ID: 26452982
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. [Hormonal contraception and risk of venous thromboembolism: When to ask for an assessment of hemostasis? Which parameters?].
    Plu-Bureau G, Horellou MH, Gompel A, Conard J.
    Gynecol Obstet Fertil; 2008 Apr 09; 36(4):448-54. PubMed ID: 18424163
    [Abstract] [Full Text] [Related]

  • 32. [Suspension of Diane35 and its generics: an over-reaction by the French National Medicines Agency (ANSM) unfounded in the light of proven or accepted medical knowledge].
    Debarre JM.
    Ann Dermatol Venereol; 2013 Apr 09; 140(6-7):474-8. PubMed ID: 23773753
    [No Abstract] [Full Text] [Related]

  • 33. Oral contraceptives and venous thromboembolism consensus opinion from an international workshop held in Berlin, Germany in December 2009.
    Reid RL, Westhoff C, Mansour D, de Vries C, Verhaeghe J, Boschitsch E, Gompel A, Birkhäuser M, Krepelka P, Dulicek P, Iversen OE, Khamoshina M, Dezman LV, Fruzzetti F, Szarewski A, Wilken-Jensen C, Seidman D, Kaaja R, Shapiro S.
    J Fam Plann Reprod Health Care; 2010 Jul 09; 36(3):117-22. PubMed ID: 20659363
    [No Abstract] [Full Text] [Related]

  • 34. [Selected aspects of oral contraception side effects].
    Wolski H.
    Ginekol Pol; 2014 Dec 09; 85(12):944-9. PubMed ID: 25669065
    [Abstract] [Full Text] [Related]

  • 35. Contraceptive for obese women: considerations.
    Kelsey B.
    Nurse Pract; 2010 Mar 09; 35(3):24-31; quiz 31-2. PubMed ID: 20164732
    [No Abstract] [Full Text] [Related]

  • 36. [Venous thromboembolism and oral contraception].
    Veljković M, Popovć J.
    Med Pregl; 2010 Mar 09; 63(5-6):376-9. PubMed ID: 21186550
    [Abstract] [Full Text] [Related]

  • 37. Oral oestrogen-progestagen contraceptives, menopausal treatment, and cancer.
    Shapiro S.
    Lancet Oncol; 2005 Oct 09; 6(10):736; author reply 737. PubMed ID: 16198976
    [No Abstract] [Full Text] [Related]

  • 38. Thromboembolic events in women exposed to hormonal contraception or cyproterone acetate in 2012: a cross-sectional observational study in 30 French public hospitals.
    Gourbil M, Grandvuillemin A, Beyens MN, Massy N, Gras V, D'Amico A, Miremont-Salamé G, Petitpain N, French Network of Regional Pharmacovigilance Centres.
    Drug Saf; 2014 Apr 09; 37(4):269-82. PubMed ID: 24634164
    [Abstract] [Full Text] [Related]

  • 39. The risk of thromboembolism and use of combined oral contraceptives: a comment.
    Birkhäuser M, Böttcher B, Germeyer A, Hadji P, Imthurn B, Mueck AO, Neulen J, Stute P, Thaler CJ, Wiegratz I, Wildt L.
    BJOG; 2023 Jun 09; 130(7):844-845. PubMed ID: 36890428
    [No Abstract] [Full Text] [Related]

  • 40. The truth about oral contraceptives and venous thromboembolism.
    Shulman LP, Goldzieher JW.
    J Reprod Med; 2003 Nov 09; 48(11 Suppl):930-8. PubMed ID: 14686030
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 11.